Intracellular tubercle bacilli (TB) reside in vacuoles in infected human macrophages (MPs). The Tubercle bacilli (TB) in infected human macrophages (MPs) reside in vacuoles (4). These vacuoles might be phagolysosomes, which would be acidic and have several acid-dependent enzymes and activities (18). The presumed vacuolar acidity is thought to affect the activities of certain anti-TB drugs. It is supposed to decrease that of streptomycin (SM) (7) and increase that of pyrazinamide (PZA) (21, 22, 27) .
Tubercle bacilli (TB) in infected human macrophages (MPs) reside in vacuoles (4) . These vacuoles might be phagolysosomes, which would be acidic and have several acid-dependent enzymes and activities (18) . The presumed vacuolar acidity is thought to affect the activities of certain anti-TB drugs. It is supposed to decrease that of streptomycin (SM) (7) and increase that of pyrazinamide (PZA) (21, 22, 27) .
Chloroquine (CQ) is a drug which is widely used against malaria and certain kinds of chronic inflammatory diseases (3, 28) . It is also used experimentally to study the acidic vacuoles of animal cells (16, 24) , because it is a lysosomotropic base (13, 28) which can increase the pH of these vacuoles and inhibit their acid-dependent activities (16, 24) . Thus, it inhibits malaria parasites by concentrating in the parasite's food vacuoles (lysosomes), raising their pH, and interfering with their digestive functions. This deprives the parasites of critical nutrients (13) . Similarly, CQ can raise the pH of phagolysosomes in mammalian cells and affect their digestive functions (16, 18, 24) . If TB do live in acid phagolysosomes in MPs and CQ can raise the pH of these vacuoles, then this drug should increase the anti-TB effectiveness of SM and lower that of PZA. This was tested in the experiments described here. While CQ enhanced the effectiveness of SM, as expected, it did not suppress that of PZA. Also, unexpectedly, it was itself able to inhibit TB in MPs, and it enhanced the anti-TB activity of another drug, isoniazid (INH), whose activity is not pH sensitive.
( (11) . The experimental drugs were added to this medium once, immediately following the infection, at the concentrations indicated in descriptions of the experiments. The infected MPs were incubated with or without the drugs for 7 days following the infection.
Counts of bacilli. Counts of bacilli were made from samples of the infected MPs taken at 30 min after infection (time zero) and 4 and 7 days after infection. The procedure for lysing the samples of infected MPs with sodium dodecyl sulfate, neutralizing the lysate with bovine serum albumin, diluting it, and plating samples of it onto 7H10 agar has been described in detail previously (4, 11) . The results obtained were CFU counts of TB growing on the 7H10 agar. These indicate the numbers of living TB in the MP lysates at the various times of sampling. The CFU is given as the number per ml of MP lysate. One milliliter of lysate was the product of an average of 105 lysed MPs. Samples of MPs were observed by phase microscopy and by conventional microscopy, after fixing and staining, for counts of the MPs and verification of cell culture health. The numbers and characteristics of the MPs in the various experimental groups reported in these experiments were comparable.
Effect of CQ against TB in bacteriologic medium. The effect of CQ against TB in bacteriologic medium was tested as described previously (9) . Briefly, 0.15-ml volumes of TBinoculated 7H9 medium were used to make twofold dilutions of CQ from a maximum concentration of 8 mg/ml downward. There was also a medium-only negative control. The titration was done in triplicate in 96-well microtiter dishes. The dishes were incubated for 7 days at 37°C. At the end of incubation the amount of bacterial growth was estimated on a 0 to 4+ scale in comparison with the growth in medium alone. Samples were also taken from each well, diluted to 2 ml with 7H9 medium, sonicated to disperse the bacteria, and diluted further in 10-fold steps for plating on 7H10 agar and counting of CFU.
Drugs. CQ (diphosphate salt; no. C-6628), PZA (no. P-7136), and INH (isonicotinic acid hydrazide, free base; no. I 3377) were purchased from Sigma Chemical Co., St. Louis, Mo. Streptomycin sulfate, USP, was purchased from Pfizer Inc., New York, N.Y. 1,25(OH)2-vitamin D3 (1,25-D3) and 25-OH-vitamin D3 (25-D3) were gifts of Milan R. Uskokovic, Hoffmann-La Roche Inc., Nutley, N.J. CQ, SM, PZA, and INH were dissolved and diluted in RPMI 1640 medium to the final concentrations needed and were sterilized by passing them t4rough a membrane filter. The vitamin D metabolites were made up in stock solutions of 1 mg in 1.5 ml of 95% ethanol and stored at -20°C. For use, they were diluted directly into the culture medium that was already added to the infected MPs (5) . Previous experiments (5) have shown that the small amount of ethanol added to these cultures does not affect the results.
Method of reporting results. For all experiments, 0-, 4-, and 7-day counts of CFU were made. However, to simplify presentation of results, Fig. 1 to 5 show only the 0-(baseline) and 7-day counts, that is, the 7-day change in CFU. Figures 2 to 5 show results from a single experiment. However, every experiment was repeated for confirmation at least once by using blood from a different donor. Standard errors of the means given in Fig. 1 to 5 were determined by Student's t distribution from the five CFU counts recorded for each experimental condition.
RESULTS
Titration of CQ against TB in MPs. The range of the lowest CQ concentrations effective against TB in human MPs was determined from several experiments. The MPs were infected, and the drug was added to the MP culture medium once immediately after infection. Results from three experiments using blood from two different donors are given in Fig. 1A . Results are mean CFU of TB per ml of MP lysate at 7 days after infection. Each experiment included a control without drug. Also, for comparison, there was a group treated similarly with 40 ,ug of PZA per ml. This is the lowest concentration of PZA which is consistently effective in human MPs (8) . CQ was effective at a lower concentration in subject 1 MPs than in subject 2 MPs. The lowest concentration that was regularly effective in all subjects for this regimen of use was 10 jg/ml.
Titration of CQ against TB in 7H9 broth. Figure 1B gives the results by CFU counts by titrating CQ directly against TB in bacteriologic culture medium. The concentrations are expressed in milligrams per milliliter, because high concentrations of CQ were needed to inhibit TB outside of MPs. Very high concentrations were able to kill TB. At 0.5 mg/ml, CQ inhibited TB in broth approximately as much as 10 jig/ml could in MP (cf. Fig. 1A ).
CQ was also tested in 7H9 broth against the virulent 7497 strain of serovar 4 Mycobacterium avium (10). It did not inhibit M. avium even at the highest concentration used (8 mg/ml).
Cooperation between CQ and SM against TB in MPs. MPs from subject 3 were infected and then incubated for 7 days in three different concentrations of SM without or with 10 ,ug of CQ per ml. The drugs were added to the culture medium once, immediately after infection. The results are given in Fig. 2 . When used alone, only the 5-,ug/ml concentration of SM was significantly effective. When CQ was present, 1 ,ug of SM per ml became effective, and the effectiveness of the 5-,ug/ml concentration was increased considerably.
Interactions between CQ, PZA, and INH against TB in MPs. CQ was tested in combination with PZA, INH, or both, which were used at their MICs against TB in human MPs (8, 9) . MPs from subject 4 were used. The results are given in Fig. 3 . CQ was somewhat more effective in this subject than it was in the others. It was significantly more inhibitory than PZA. INH alone at 0.05 ,ug/ml was bacteriostatic or slowly bactericidal, as reported previously (9 MPs from subject 5 were incubated with 1,25-D3, CQ, or PZA and combinations of these drugs (Fig. 4) (25) . CQ was expected to block hydroxylative production from the nearly unprotective 25-D3 (4a, 26) of the protective 1,25-D3. CQ was used at 10 p,g/ml with 4 ,g of the two metabolites per ml. The results (Fig. 5) show that CQ and 25-D3 used together provided stronger anti-TB protection than did either one alone. These results were confirmed in a separate experiment with blood from a different donor. DISCUSSION CQ originally was developed and selected in the United States as an antimalarial drug substitute for quinine, when quinine became unavailable at the beginning of World War II (17) . It has been used as such in millions of people (17, 20, 28) . It is also effective against rheumatoid arthritis and is used more for that now than it is against malaria (12, 20, 28) .
CQ probably inhibits malaria plasmodia by concentrating in their lysosomal food vacuoles. Lysosomes use aciddependent hydrolases to digest substances delivered to them by phagosomes and endosomes (18, 19) . CQ is actively pumped into lysosomes (17, 20) , where, as a weak base, it neutralizes phagolysosomal acidity (16, 20, 24) . Effects of 1,25-D3 (4 ,ug/ml), PZA (40 ,ug/ml), and CQ (10 ,ug/ml) used alone or in combinations against TB in MPs. Experimental conditions and data are as described in the legend to Fig. 2.   FIG. 3 . Effects of INH (0.05 Fjg/ml), PZA (40 V±g/ml), and CQ (10 ,ug/ml) used alone or in combinations against TB in MPs. Experimental conditions and data are as described in the legend to Fig. 2. presses lysosome digestive activities, and in patients with malaria, treatment inhibits the parasites by depriving them of critical nutrients (13) . These properties of CQ also have made it useful experimentally for changing the pH of lysosomes in mammalian cells to study various acid-and lysosome-dependent cell functions (16, 24) .
In this study we tested CQ for its ability to enhance the anti-TB effectiveness of SM in human MPs by raising phagolysosomal pH, because virulent TB are thought to multiply intracellularly within phagolysosomes (4) and the low pH of these vesicles is assumed to diminish the antibacterial effectiveness of SM (7). CQ performed as expected, decreasing by fivefold the minimal concentration of SM that could inhibit TB in MPs. It enabled SM to kill some intracellular bacilli, when SM alone was only able to slow their growth. However, the reason for cooperation between CQ and SM is unclear, because CQ itself was found to be able to inhibit intracellular TB. CQ slowed or stopped the growth of the TB in MPs when CQ was added to the MP cultures at concentrations down to 2.5 jxg/ml (0.005 mM) (Fig. 1A) . This concentration is in the range of 0.5 to 5 ,ug/ml of plasma which is commonly attained in CQ-treated patients with rheumatoid arthritis (12) . At 1 mM or higher, CQ can inhibit some species of bacteria by directly impairing DNA and RNA synthesis (2) . TB apparently are among these susceptible species of bacteria, because they were inhibited by CQ in 7H9 broth at 500 ,ug/ml (1 mM) and were killed by concentrations of 2,000 jig/ml or more (Fig. 1B) . These concentrations were much higher than were needed for inhibition of TB in MPs. However, human monocytic phagocytes concentrate CQ rapidly as much as 100-fold, and at the concentrations achieved in plasma during therapy of rheumatoid arthritis, they accumulate CQ at concentrations of 150 p.g/ml and higher (1, 12) . Furthermore, TB have acidic surfaces which could further increase CQ concentrations within infected phagolysosomes (14) . When CQ was in contact with the TB in the infected phagolysosomes, CQ may have reached concentrations that could inhibit the bacteria directly. The ability of CQ to inhibit TB is selective, because it was not able to inhibit M. avium, even at 8,000 p.g/ml (16 mM).
If CQ enhanced the anti-TB effectiveness of SM solely by raising phagolysosomal pH (16, 19, 24) as was originally postulated for these experiments, then it should have proportionally decreased the effectiveness of PZA, because PZA requires a low pH to inhibit TB (21, 22, 27 direct role in the cooperation between CQ and the various drugs tested against the intracellular TB. The natively low pH of lysosomes could, however, be important indirectly in the anti-TB activity of CQ in MPs by promoting the intravacuolar accumulation of CQ (12, 19, 28 (15) mentioned briefly some experiments on lysosome-phagosome fusion in which they found that 0.02 mM (10 ,ug/ml) CQ was able to inhibit TB in cultured mouse MPs. The differences between CFU counts for treated and untreated MPs were not large (e.g., 0.5 log units; Fig. 1A ). However, they were comparable to such differences as were produced in this experimental model by clinically relevant concentrations of PZA (6, 8) which, because of its notable cooperation with other antituberculosis drugs, has become one of the two drugs most widely used against tuberculosis. Our results suggest, therefore, that CQ and related drugs may be worth further investigation for possible use in antituberculosis chemotherapy.
